Chinese drugmaker Fosun Pharma (SFOSF) on Tuesday announced a global licensing agreement with Pfizer (PFE) to hand the U.S. pharma giant exclusive rights to its oral GLP-1 drugs in a deal worth up to ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to appease jittery investors.

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

Pfizer on Tuesday joined the cavalcade of big pharma firms hunting for novel weight loss drugs in the laboratories of Chinese biotechs, even as U.S. authorities ramp up efforts to undercut the growing ...

Eli Lilly (LLY), Pfizer (PFE), and Johnson & Johnson (JNJ) secured spots on China's first innovative drug catalog for private insurance, featuring 19 high-cost medicines for conditions like cancer, ...

Pfizer PFE stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations. Pfizer expects total revenues for 2026 ...